STOCK TITAN

Armistice Capital/Steven Boyd Disclose 336,000-Share Holding in FGEN

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A single investment manager reports an 8.31% stake, signaling a meaningful equity position disclosed under Schedule 13G/A.

Armistice Capital's filing shows it manages a material minority stake in FibroGen through its Master Fund and reports shared voting and dispositive power over 336,000 shares. This is a passive ownership disclosure consistent with Schedule 13G/A practice where the filer states holdings are in the ordinary course of business and not intended to influence control. The reported percentage is calculated using the issuer's share count from its recent 10-Q and therefore reflects a non-trivial ownership level that could be relevant to shareholder composition analyses.

TL;DR: The filing documents joint reporting by manager and individual and clarifies governance/control relationships.

The statement delineates Armistice Capital's role as investment manager and Mr. Boyd's position as managing member, with both acknowledging shared voting and dispositive authority for the reported shares. The Master Fund's disclaimer of direct beneficial ownership due to the investment management agreement is explicitly stated, reducing ambiguity about who holds legal title versus who directs voting and disposition. The joint filing statement confirms responsibility-sharing for amendments and accuracy of reported information.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/15/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/15/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Fibrogen Inc

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Latest SEC Filings

FGEN Stock Data

34.10M
3.98M
1.57%
26.51%
3.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO